Latest news
Iconovo participates in investor meeting in Stockholm (Only in Swedish)
Iconovo AB utvecklar inhalatorer som används mot våra stora folksjukdomar astma och kol. Klicka här för att ta del av presentationen från Aktiedagen…
Iconovo is to be listed on the Nasdaq First North Sweden marketplace
Iconovo AB publ announces an initial public offering and plans for its shares to be listed on the Nasdaq First North Sweden marketplace. (Swedish only).
Iconovo…
Press releases
Feb 12, 2026, 08:30
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Feb 12, 2026, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Jan 15, 2026, 10:15
News
IR
English
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Jan 15, 2026, 10:15
News
IR
Swedish
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Jan 13, 2026, 13:40
News
IR
English
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Jan 13, 2026, 13:40
News
IR
Swedish
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
